RC
SIOX

RBF Capital’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

RBF Capital’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,000
Closed -$24K – 427
2018
Q4 		$24K Hold
3,000
– – ﹤0.01% 403
2018
Q3 		$58K Hold
3,000
– – 0.01% 398
2018
Q2 		$57K Buy
+3,000
New +$44.2K 0.01% 384

Other funds holding SIOX

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

RBF Capital's SIOX Position: Q1 2019 in Review

RBF Capital sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2019, closing a stake of 3,000 shares — an estimated $24K sold.

RBF Capital first reported a position in SIOX in Q2 2018 and held it in 3 quarters. The position peaked at $58K in Q3 2018. 57 funds tracked by Wall St. Rank hold SIOX as of Q1 2019.

  • RBF Capital reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • RBF Capital sold 3,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2019, an estimated $24K.
  • RBF Capital first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • RBF Capital's Sio Gene Therapies Inc. Common Stock position peaked at $58K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2019.

Based on RBF Capital's 13F filing for Q1 2019, filed 15 May 2019.